dabrafenib + vemurafenib

Dabrafenib and vemurafenib are both small molecule inhibitors targeting the BRAF kinase, specifically the BRAF V600E mutation. Both drugs are approved as monotherapies for unresectable or metastatic melanoma with a BRAF V600E mutation. However, they are not used together in clinical practice or trials due to overlapping mechanisms and toxicity profiles. Instead, each is typically combined with a MEK inhibitor (dabrafenib with trametinib; vemurafenib with cobimetinib) to improve efficacy and reduce resistance seen with monotherapy. There is no evidence supporting the use of dabrafenib plus vemurafenib as a combination regimen in any indication[1][2][3]. Both drugs act by inhibiting aberrant MAPK pathway signaling driven by mutant BRAF.